Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen K Chew

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623Halle C F Moore, Stephanie J Green, Julie R Gralow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
CA: a Cancer Journal for Clinicians|September 30, 2020
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?Pelin Cinar, Richard Bold, Bryn A Bosslet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancerHelen K Chew, James H Doroshow, Paul Frankel, et al.
JNCI Cancer Spectrum|March 15, 2026
Long-Term follow-up of S0221, comparing alternative Dose-Schedules of anthracycline/taxane therapy in early breast cancerAzka Ali, William E Barlow, Halle C F Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerGeorge T Budd, William E Barlow, Halle C F Moore, et al.
Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083George Somlo, Paul H Frankel, Banu K Arun, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623Halle C F Moore, Stephanie J Green, Julie R Gralow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyCarol M Richman, Sally J Denardo, Robert T O'Donnell, et al.
CA: a Cancer Journal for Clinicians|September 30, 2020
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?Pelin Cinar, Richard Bold, Bryn A Bosslet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancerHelen K Chew, James H Doroshow, Paul Frankel, et al.
JNCI Cancer Spectrum|March 15, 2026
Long-Term follow-up of S0221, comparing alternative Dose-Schedules of anthracycline/taxane therapy in early breast cancerAzka Ali, William E Barlow, Halle C F Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerGeorge T Budd, William E Barlow, Halle C F Moore, et al.
Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2017
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i>- or <i>BRCA2</i>-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083George Somlo, Paul H Frankel, Banu K Arun, et al.
Pageof 3